What can healthcare leaders learn from Mylan? 3 key points to consider in crises

Practice Management

Intense criticism has clouded above Mylan for increasing EpiPen's price by more than 450 percent since 2004. In response, the pharmaceutical company announced it will offer a $300 generic alterative.

Health policy analyst Paul Keckley, PhD, offers three key lessons other healthcare organizations best heed from the Mylan controversy, according to Hospitals & Health Networks.


Here are three key points:


1. Healthcare doesn't understand the meaning of "secrets." From patients who are quick to discuss their experiences to employees who don't hesitate to expand on their company cultures, the inner workings of just about anything will eventually come to light in this industry.


2. Company boards run the show, and can just as easily destroy a company as they can make a company. Therefore, boards must remember to guide a company in the direction balanced by "profit and social purpose," and offer a transparent view of pricing strategies to both those inside and outside the company.


3. A CEO is the face of a company, especially in times of crisis, and must present an even-tempered, trustworthy demeanor. If they fail to do so, the company's longevity and reputation may very well be decided in a moment.


Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers